ArticleAAPS PharmSciTech2025
Injectable Hyaluronic Acid Hydrogels Crosslinked by Structure-engineered Aldehyde-functionalized β-Cyclodextrin Derivatives for Long-term Controlled Voriconazole Delivery.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging Preclinical and Clinical Gaps in Ocular Therapeutics: Hydrogel Drug Delivery and 3D Tissue Models.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term controlled release in drug-loaded injectable hydrogels is challenging in the injection-based treatments of ocular diseases. Herein, injectable hyaluronic acid (HA)-based hydrogels were synthesized in situ via Schiff base reaction between amino-functionalized hyaluronic acid (NHA) and three aldehyde-functionalized β-cyclodextrin (β-CD) derivatives: aldehyde β-cyclodextrin (ACD), aldehyde linear poly-β-cyclodextrin (ALCD), and aldehyde branched poly-β-cyclodextrin (ABCD). The composition, structure, and properties of the prepared hydrogels were analyzed using Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and dynamic rheometry. The hydrogels exhibited a pore size range of 50-250 μm, a swelling degree of 27.1-45.0%, and a gelation time of 60-300 s, demonstrating suitable microstructural and rheological properties for clinical applications. By leveraging the dual functionality of the aldehyde β-CD derivatives as both crosslinking agents and drug carriers (Voriconazole (VCZ) was as a model drug), the hydrogels achieved long-term controlled release (> 60 days) with quasi-zero-order kinetics in the later stage, alongside excellent cellular compatibility, particularly for NHA/ACD (R
Indexed as
Identifiers
41199019What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.